Company news: Suven Life Sciences

Suven Life Sciences on Tuesday informed the exchanges of the receipt of one product patent from Canada and another from Sri Lanka for the new chemical entity (NCE) for treatment of disorders associated with neuro-degenerative diseases. The patents are valid through 2034 and 2026, respectively. The granted claims of the patents include the class of selective H3 and 5-HT6 compounds respectively, and are being developed as therapeutic agents for neurodegenerative disorders such as Alzheimer's disease, attention-deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease and Schizophrenia, as well as sleep disorders like Narcolepsy, etc. Shares of Suven Life closed 2.9 per cent higher at ₹274.15 on the BSE.